An observational study in Cancer, sponsored by Abramson Cancer Center at Penn Medicine. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-13.
Sponsored by Abramson Cancer Center at Penn Medicine · Observational
The purpose of the study is to understand patient interest in telehealth and digital tools for pre-test genetic education and/or disclosure of genetic test results. Participants will receive telehealth genetic counseling in the home and may be offered various digital tools to help with the counseling and testing process. These are optional and participants can still speak with a genetic counselor if they wish.
The goal of the eREACH3 Study is to evaluate the implementation of these tools into remote genetic services, evaluating uptake and use of digital tools and outcomes in representative clinical populations. The initial protocol will include two genetic counseling visits, providing comparison outcomes. Future amendments will be provided as digital tools are ready for implementation.
Specific Aim 1: (Reach) Evaluate the uptake, use and acceptability of digital delivery alternatives in remote genetic services provided as alternatives to the traditional two-visit model with a genetic counselor.
Specific Aim 2: (Effectiveness) Evaluate short-term and 6 month patient reported cognitive, affective and behavioral outcomes (2a) with remote genetic services and digital alternatives in representative clinical populations and moderators of outcomes (2b).
Specific Aim 3: (Implementation) Evaluate provider time associated with implementation of remote telehealth services and digital delivery alternatives and barriers and facilitators to future clinical implementation.
9,371 studies on the registry are indexed under Neoplasms; 2,492 are open to participants now.
This study's planned enrollment of 360 is above the median of 205 across 1,684 observational studies indexed under Neoplasms.
Browse Neoplasms studies →Abramson Cancer Center at Penn Medicine is the lead sponsor of 446 studies on the registry; 86 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 14 (44%) have results posted.
Counted across the registry records on this site, refreshed daily.
Individuals with personal or family history of cancer.
Exclusion Criteria:
All participants will be offered remote telehealth Visit 1 services by telephone or real-time videoconference or by a chatbot (patient choice).
Uptake of Visit 1
Participant completion of Visit 1 (yes/no)
Time frame: Through 6 months
Uptake of Digital Visit 1
Participant completion of digital intervention as an alternative for Visit 1 (yes/no)
Time frame: Through 6 months
Uptake of genetic testing
Participant completion of genetic testing and received results/Visit 2 (yes/no)
Time frame: Through 6 months
The KnowGene Scale
Change in Knowledge - Score Range = 0-16, Higher score = Better outcome
Time frame: Through study completion, an average of 6 months
Test result recall
Recall of genetic testing results
Time frame: Through study completion, an average of 6 months
Impact of Events Scale (IES)
Change in Cancer Specific Distress - Score Range = 0-40, Lower score = Better outcome
Time frame: Through study completion, an average of 6 months
Satisfaction with genetic services
Differences in satisfaction - Score Range = 14-70, Higher score = Better outcome
Time frame: Through study completion, an average of 6 months
Multi-dimensional Impact of Cancer Risk Assessment Questionnaire (MICRA)
Change in Uncertainty - Score Range = 0-85, Lower score = Better outcome
Time frame: Through study completion, an average of 6 months
Decisional Regret Scale
Differences in decisional regret - Score Range = 5-25, Lower score = Better outcome
Time frame: Through study completion, an average of 6 months
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Abramson Cancer Center at Penn Medicine